145 related articles for article (PubMed ID: 36169975)
1. Interrogation of TERT promoter hotspot mutations in ameloblastoma and ameloblastic carcinoma.
Magalhães MCSV; Felix FA; Guimarães LM; Dos Santos JN; de Marco LA; Gomez RS; Gomes CC; de Sousa SF
J Oral Pathol Med; 2023 Mar; 52(3):271-275. PubMed ID: 36169975
[TBL] [Abstract][Full Text] [Related]
2. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours.
Diniz MG; Gomes CC; Guimarães BV; Castro WH; Lacerda JC; Cardoso SV; de Faria PR; Dias FL; Eisenberg AL; Loyola AM; Gomez RS
Tumour Biol; 2015 Jul; 36(7):5649-53. PubMed ID: 25854168
[TBL] [Abstract][Full Text] [Related]
3. Advances in Detecting Low Prevalence Somatic
da Costa VR; Bim LV; Pacheco E Silva LDP; Colloza-Gama GA; Bastos AU; Delcelo R; Oler G; Cerutti JM
Front Endocrinol (Lausanne); 2021; 12():643151. PubMed ID: 33776938
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
5. DNA ploidy of ameloblastoma and ameloblastic carcinoma of the jaws. Analysis by image and flow cytometry.
Müller S; DeRose PB; Cohen C
Arch Pathol Lab Med; 1993 Nov; 117(11):1126-31. PubMed ID: 8239934
[TBL] [Abstract][Full Text] [Related]
6. [BRAF V600E expression in ameloblastomas, ameloblastic carcinomas and cysts].
Pei J; Zhang L; Jia YX; Chen WH
Shanghai Kou Qiang Yi Xue; 2023 Dec; 32(6):630-634. PubMed ID: 38494972
[TBL] [Abstract][Full Text] [Related]
7. Ameloblastic carcinoma developing in preexisting ameloblastoma with a mutation of the p53 gene: a case report.
Nobusawa A; Sano T; Yokoo S; Oyama T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Nov; 118(5):e146-50. PubMed ID: 24906942
[TBL] [Abstract][Full Text] [Related]
8. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
9. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors.
Liu T; Brown TC; Juhlin CC; Andreasson A; Wang N; Bäckdahl M; Healy JM; Prasad ML; Korah R; Carling T; Xu D; Larsson C
Endocr Relat Cancer; 2014 Jun; 21(3):427-34. PubMed ID: 24803525
[TBL] [Abstract][Full Text] [Related]
10. BRAFV600E mutation in the diagnosis of unicystic ameloblastoma.
Pereira NB; Pereira KM; Coura BP; Diniz MG; de Castro WH; Gomes CC; Gomez RS
J Oral Pathol Med; 2016 Nov; 45(10):780-785. PubMed ID: 27084044
[TBL] [Abstract][Full Text] [Related]
11. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia.
Papathomas TG; Oudijk L; Zwarthoff EC; Post E; Duijkers FA; van Noesel MM; Hofland LJ; Pollard PJ; Maher ER; Restuccia DF; Feelders RA; Franssen GJ; Timmers HJ; Sleijfer S; de Herder WW; de Krijger RR; Dinjens WN; Korpershoek E
Endocr Relat Cancer; 2014 Aug; 21(4):653-61. PubMed ID: 24951106
[TBL] [Abstract][Full Text] [Related]
12. Hypermethylation of p16 tumor-suppressor gene in ameloblastic carcinoma, ameloblastoma, and dental follicles.
Khojasteh A; Khodayari A; Rahimi F; Ghaderian MH; Jafarian M; Nayebi A; Akbarzadeh Najar R; Tabatabayipanah A; Jahangirnia A
J Oral Maxillofac Surg; 2013 Jan; 71(1):62-5. PubMed ID: 22705216
[TBL] [Abstract][Full Text] [Related]
13. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.
Huang DS; Wang Z; He XJ; Diplas BH; Yang R; Killela PJ; Meng Q; Ye ZY; Wang W; Jiang XT; Xu L; He XL; Zhao ZS; Xu WJ; Wang HJ; Ma YY; Xia YJ; Li L; Zhang RX; Jin T; Zhao ZK; Xu J; Yu S; Wu F; Liang J; Wang S; Jiao Y; Yan H; Tao HQ
Eur J Cancer; 2015 May; 51(8):969-76. PubMed ID: 25843513
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
15. DNA content and clinicopathological features aid in distinguishing ameloblastic carcinoma from ameloblastoma.
Penafort PVM; Rocha AC; Mariano FV; Dos Santos JN; Oliveira MC; Vargas PA; Sperandio M
J Oral Pathol Med; 2024 Jan; 53(1):70-78. PubMed ID: 38163857
[TBL] [Abstract][Full Text] [Related]
16. BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may affect MAPK activation differently depending on tumor type.
Oh KY; Kim JH; Cho SD; Yoon HJ; Lee JI; Hong SD
Genes Chromosomes Cancer; 2022 Aug; 61(8):481-490. PubMed ID: 35353428
[TBL] [Abstract][Full Text] [Related]
17. Gene mutation analysis and immunohistochemical study of beta-catenin in odontogenic tumors.
Miyake T; Tanaka Y; Kato K; Tanaka M; Sato Y; Ijiri R; Inayama Y; Ito Y; Aoki S; Kawabe R; Tohnai I
Pathol Int; 2006 Dec; 56(12):732-7. PubMed ID: 17096730
[TBL] [Abstract][Full Text] [Related]
18. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
[TBL] [Abstract][Full Text] [Related]
19. Distinct TERT promoter C228T and C250T mutations in a patient with an oligodendroglioma: A case report.
Ishi Y; Okada H; Okamoto M; Motegi H; Tanaka S; Mitsuhashi T; Yamaguchi S
Neuropathology; 2021 Jun; 41(3):236-242. PubMed ID: 33899270
[TBL] [Abstract][Full Text] [Related]
20. Regulatory Single Nucleotide Polymorphism Increases TERT Promoter Activity in Thyroid Carcinoma Cells.
Hirokawa T; Arimasu Y; Chiba T; Nakazato Y; Fujiwara M; Kamma H
Pathobiology; 2020; 87(6):338-344. PubMed ID: 33227798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
